Androgen News and Research

RSS

Biomira Stimuvax prostate cancer study results published

Biomira Inc. has announced publication of study results showing that Stimuvax, formerly known as BLP25 Liposome Vaccine or L-BLP25, could slow rising Prostate Specific Antigen (PSA) levels in some post-surgical prostate cancer patients

20 Jul 2006

Intermittent androgen deprivation in biochemical recurrence of prostate cancer after radiotherapy

Intermittent androgen deprivation (IAD) is commonly used in the treatment of CaP, which theoretically may delay the development of hormone resistance.

29 Jun 2006

Obesity associated with less favorable outcome after radiation therapy for prostate cancer

Obese men with prostate cancer are at higher risk for treatment failure after primary radiation therapy, according to a new study.

27 Jun 2006

Few well performed studies address management of lymph node positive prostate cancer

Dr. Gregory Swanson and associates from the University of Texas, San Antonio Health Science Center reviews the data for various treatment options in patients with lymph node positive prostate cancer (CaP).

27 Jun 2006

Advanced prostate cancer can be treated successfully with intermittent chemotherapy

Advanced prostate cancer can be treated successfully with intermittent chemotherapy, according to a study conducted by Oregon Health & Science University Cancer Institute scientists.

6 Jun 2006

Monitoring anemia provides clues to prostate cancer treatment response

Researchers from the Oregon Health & Science University Cancer Institute and Southwest Oncology Group have identified a new method of determining how men with advanced prostate cancer will respond to treatment.

1 Jun 2006

Novel protein JHDM2A offers new look at male hormone regulation

For the second time in less than a year, University of North Carolina at Chapel Hill scientists have purified a novel protein and have shown it can alter gene activity by reversing a molecular modification previously thought permanent.

8 May 2006

A contraceptive pill for men!

According to a Sydney scientist a hormone-based contraceptive for men has the ability to reverse its effect just four months after stopping its use.

1 May 2006

Novel and important benefits of vitamin D and the problems associated with vitamin D deficiency

...will be discussed at the American Association of Clinical Endocrinologists (AACE) Fifteenth Annual Meeting and Clinical Congress, April 26-30, at the Hyatt Regency Chicago.

19 Apr 2006

Prostate cancer research may be faster with prostate-specific antigen endpoints

A new study from Columbia University Medical Center researchers at NewYork-Presbyterian Hospital/Columbia, who are members of the Southwest Oncology Group (SWOG), suggests that certain changes in prostate-specific antigen (PSA) levels may serve as surrogate endpoints for prostate cancer survival.

18 Apr 2006

Usage and outcomes of primary androgen deprivation therapy for localized prostate cancer

In the online March 2006 version of Cancer, Dr. Kawakami and associates report from the CaPSURE database that primary androgen deprivation therapy (PADT) is used in 14% of prostate cancer (CaP) patients with reasonable outcomes at approximately 5 years follow-up.

11 Apr 2006

Newly discovered testosterone effect may act on prostate cancer

A newly-discovered mode of action of testosterone is showing great promise in the fight against prostate cancer, with tests showing a 60% reduction in tumor size in mice.

6 Apr 2006

Ingredient in red peppers inhibits prostate cancer in laboratory studies

Capsaicin is the pungent ingredient in red peppers and is presently used as a topical pain reliever. Now, a new study shows it may be justified to evaluate capsaicin for inhibiting prostate cancer (CaP) in patients.

5 Apr 2006

Capsaicin drives prostate cancer cells to kill themselves

Capsaicin, the stuff that turns up the heat in jalapeqos, not only causes the tongue to burn, it also drives prostate cancer cells to kill themselves, according to studies published in the March 15 issue of Cancer Research.

15 Mar 2006

$Hormone therapy for advanced prostate cancer can lead to bone loss and fractures$

Hormone therapy for advanced prostate cancer can lead to bone loss and fractures

A common type of treatment used to protect bone density in menopausal women is also an effective therapy for advanced prostate cancer patients during the first year of hormone therapy, according to a new Oregon Health & Science University Cancer Institute study.

1 Mar 2006

Oral agent alendronate may help men with prostate cancer suffering from bone loss

Men with prostate cancer who experience bone loss from cancer treatment could benefit from a weekly oral therapy commonly given to women with osteoporosis, according to a study presented by the University of Pittsburgh Medical Center (UPMC) at the American Society of Clinical Oncology Prostate Cancer Symposium, Feb. 24 to 26 at the San Francisco Marriott.

27 Feb 2006

Androgen deprivation therapy does not prevent prostate cancer from spreading

Oregon Health & Science University Cancer Institute researchers wanted to know if depriving men of testosterone actually keeps cancer from spreading beyond the prostate.

27 Feb 2006

Inflammatory reaction drives hormone resistance in cancer

In the journal Cell, researchers report new evidence to explain why prostate cancer and other hormone-dependent cancers may become resistant to hormone therapies.

21 Feb 2006

Macrophage signaling may affect hormone resistance in prostate tumors

Interaction between prostate cancer cells and immune cells called macrophages may be a source of inflammatory signals capable of impacting the effectiveness of androgen antagonists, the most common and effective treatment for prostate cancer, according to a new study by researchers at the University of California, San Diego (UCSD) School of Medicine.

16 Feb 2006

Research indicates birth control pill could cause long-term problems with testosterone

In the January issue of The Journal of Sexual Medicine, researchers have published a new investigation measuring sex hormone binding globulin (SHBG) before and after discontinuation of the oral contraceptive pill.

6 Jan 2006